A common epitope on human tumor necrosis factor alpha and the autoantigen 'S-antigen/arrestin' induces TNF-alpha production by Stiemer, R. H. et al.
Journal of A utoimmunity (1992) 5, 15-26 
A Common Epitope on Human Tumor  Necrosis 
Factor Alpha and the Autoantigen 'S-antigen/ 
arrestin' induces TNF-a Product ion 
Rainer H. Stiemer,*t Uwe Westenfelder,~ Heinrich Gausepohl,w 
Massoud Nlirshahi,* Anita Gundt,~ Rainer W. Frankw and 
Daniela N. M~innel~ 
* Laboratoire d'Immunopathologie de l'Oeil, IN SERM U86, Paris, France, ~Institute 
for Immunology and Genetics, German Cancer Research Center, Heidelberg, Germany 
and w of Molecular Biology, University of Heidelberg, Germany 
(Received 21 May 1991 and accepted 3 October 1991 ) 
A common ep i tope  on S -ant igen  (a r res t in ) ,  a potent  autoant igen  induc ing  
exper imenta l  auto immune uveoret in i t i s  (EAU) ,  and  on human tumor  
necros is  fac tor  a (hTNFa)  was revea led  us ing two monoc lona l  ant ibod ies  to 
S -ant igen  which  inh ib i t  EAU induct ion .  The min imal  common sequence 
for  monoc lona l  ant ibody  recogn i t ion  is GVxLxD in the S -ant igen lhTNFa 
amino  ac id  sequences.  Pept ides  conta in ing  this  sequence mot i f  exh ib i ted  
monocyte  ac t ivat ing  capac i ty  s imi la r  to the autocr ine  s t imu la tory  
capac i ty  o f  hTNFa itself .  In  the S -ant igen  this  ac t iv i ty  was located  f rom 
res idue  40 to 50, cor respond ing  to the pept ide  PVDGVVLVDPE (ep i tope  
$2). In hTNFa,  the monocyte  ac t ivat ing  capac i ty  cor re la ted  to res idue  31 to 
53, cor respond ing  to the pept ide  RRANALLANGVELRDNQLVVPSE 
(pept ide  RRAN) .  The ident i f ied  reg ions  def ine common funct iona l  
s t ruc tures  in the autoant igen  and  in the hTNFa molecu le .  The data  suggest  
a regu la tory  funct ion  of  th is  par t i cu la r  s t ruc ture  in TNFa  express ion  and  
in auto immuni ty .  
In t roduct ion 
S-antigen, a soluble protein abundant in retinal photoreceptors, is apotent autoanti- 
gen which induces experimental utoimmune uveoretinitis (EAU) and pinealitis 
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(EAP) [1, 2]. EAU is a model system for human uveoretinitis because the animal 
disease resembles certain inflammatory conditions in the human eye and sensitiz- 
ation to S-antigen is frequently detected in patients uffering from these conditions. 
S-antigen is identical to the 48 kDa protein of rod outer segments, named arrestin [3]. 
Its physiological functions in the visual transduction cascade include light- and 
ATP-induced binding to phosphorylated rhodopsin, quenching the activation of 
cGMP-dependent phosphodiesterase [4],and a possible activity as an internal Ca 2+ 
buffer in photoreceptors [5]. The complete amino acid sequence (404 amino acid 
residues) of bovine retinal S-antigen was determined in 1987 [2]. Sequence analysis 
has since been expanded to retina and pineal gland derived S-antigens from different 
mammals [2, 6, 7]. An S-antigen-like molecule was isolated from bovine brain. This 
protein is associated with a regulatory function in the ~-adrenergic receptor trans- 
duction system similar to the retinal S-antigen in the photoreceptor transduction 
system, i.e., desensitization f G-protein coupled receptors. This protein was named 
~-arrestin and exhibits 59% sequence identity with bovine retinal S-antigen [8]. 
Two S-antigen-like molecules have also been identified in Drosophila [9-12]. Mono- 
clonal antibodies (mAbs) that recognize different epitopes of retinal S-antigen also 
identified S-antigen-like proteins in the cytosol of avian and fish nucleated erythro- 
cytes [13], in extracts from several bovine organs (M. Mirshahi et al., in preparation) 
and even in plants [ 14]. The participation of S-antigen in the replication machinery 
has recently been described [ 15]. 
The mAbs $2D2 and $6H8 recognize a phylogenetically conserved antigenic 
determinant (epitope $2). Injection of these mAbs, especially mAb $2D2, inhibits 
the subsequent induction of EAU by S-antigen immunization in rats [16, 17]. The 
suppressive effect of these mAbs on EAU suggests an idiotypic regulatory mechan- 
ism and/or immunomodulatory function of the epitope $2, especially concerning 
inflammatory processes. This assumption prompted us to investigate two different 
questions: (1) a possible role of the S-antigen and epitope $2 in the induction of 
cytokines involved in inflammatory processes, i.e., human tumor necrosis factor 
alpha (hTNFa) [18] and (2) a direct influence of the EAU suppressive mAbs on the 
TNF~-mediated pleiotropic effects, for example the autocrine-stimulated hTNF~ 
gene expression and secretion [19]. 
Mater ia l s  and  methods  
Reagents 
S-antigen was isolated from bovine retinas and purified in two chromatographic 
steps as described [20]. Recombinant human (rh) TNFa  was supplied by Knoll/ 
BASF AG, Ludwigshafen, Germany. The specific activity of the material was 
8.74 x 106 U/mg protein as measured in the biological tumor cell (L929) cytotoxicity 
assay in the absence of actinomycin D [21]. 
S-antigen specific peptides and hTNFa specific peptides were synthesized in a 
continuous flow instrument constructed and operated as described earlier [22]. 
Peptide chain assembly was performed by the solid phase method on a 1% cross- 
linked polystyrene support using Fmoc-aa and in situ activation by BOP [23]. The 
synthetic peptides were purified by reverse phase HPLC. 
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Monoclonal antibodies $2D2 (IgG2b) and $6H8 (IgG2a) to S-antigen [24, 25] 
were purified from ascites fluid by affinity chromatography on S-antigen-bound 
Sepharose 4B ($6H8) or on Protein A-Sepharose 4B ($2D2) [16]. The mAb 7D1 
(IgG1) against hTNF~ and the mAbs ALB9 (IgG1), PM1 (IgG2b) and ALB2 
(IgG2a), specific for human leukocyte differentiation antigens (isotype controls) 
[26, 27], were purified from ascites fluid by affinity chromatography on Protein 
A-Sepharose 4B. 
Western-blot analysis 
Recombinant hTNFa (3 pg/lane) was electrophoresed on a SDS-12.5% poly- 
acrylamide gel and transferred to nitrocellulose membrane by electroblotting [28]. 
Non-specific binding sites were blocked with 3% BSA in PBS. Incubation with the 
purified mAbs (5 ~tg/ml in PBS containing 1% BSA) was followed by incubation 
with peroxidase-labelled rabbit anti-mouse Ig antibodies (Sigma, Deisenhofen, 
Germany), and with diaminobenzidine-H20 z in sodium acetate buffer (0.1 M, pH 
4.9) according to the manufacturer's ecommendations. 
P E P S C A N-analy sis 
Sixty-eight heptapeptides, overlapping by six amino acids (aa), from bovine retinal 
S-antigen (N-terminal residues 1-74) and 75 heptapeptides, overlapping by five aa, 
from the complete mature hTNFct molecule were synthesized on polyethylene rods, 
essentially following the strategy described by Geysen [29]. The synthesis, however, 
used Fmoc (9-fluorenylmethyloxycarbonyl) chemistry and BOP activation. The 
polyethylene rods derivatized with [3-alanine were purchased from Cambridge 
Research Biochemicals (Cambridge, UK). PEPSCAN-ELISA tests and stripping of 
the rods were carried out as described by Geysen [29]. Specific mAb binding was 
detected using horseradish peroxidase (HRP)-conjugated Protein A (Bio-Rad 
Laboratories, Richmond, VA, USA), 1:2,000 diluted. The enzymatic activity was 
revealed with the HRP substrate, 2,2'-azinobis 3-ethylbenzthiazoline-6-sulfonic 
acid 2NH4-salt (ABTS) (Serva, Heidelberg, Germany) in 0.1 M Na2HPO 4, 0.1 M 
citric acid pH 4.0, containing 0.02% H202. The reaction was stopped by removal of 
the rods after 20 min. ELISA absorbance was measured at 405 nm. 
Cell preparation 
Human peripheral mononuclear leukocytes (PMNL) were prepared from hepari- 
nized blood samples by Ficoll-Paque (Pharmacia, Freiburg, Germany) density- 
gradient centrifugation [30]. 
Northern-blot analysis 
Total cellular RNA was isolated after a 2 h incubation of 2 x 106/ml human PM.NL 
with protein or synthetic peptide preparations. The controls were cultured either 
with or without 10 pg/ml Staphylococcus aureus (Pansorbin, Calbiochem, Frankfurt, 
Germany). The RNA was analysed on a Northern blot [19] which was sequentially 
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hybridized with 32p-labelled probes generated by random priming of cDNA inserts. 
The cDNAs were (a) a 750 bp EcoRI fragment of the coding region of hTNFa 
cDNA, (b) a 530bp Barn HI-NdeI IL-lJ3 cDNA fragment (isolated from p l l ,  
supplied by U. Gubler, Hoffmann La Roche, Nutley, NJ, USA) and (c) a 560 bp 
SalI-EcoRI-[3 actin cDNA fragment. 
Determination fh TNFa production 
Human PMNL (2 x 106/0.5 ml) were cultured in RPMI 1640 (GIBCO) with 10% 
heat-inactivated fetal calf serum (GIBCO) for 20 h with protein or synthetic 
peptide preparations. The controls were cultured either with or without 10 ~tg/ml 
Staphylococcus aureus (Pansorbin, Calbiochem). Cell-free supematants were har- 
vested and stored at -20~ until they were tested for hTNFa activity. The hTNFa 
activity was determined either by ELISA specific for hTNFa [31] or by the tumor 
cell (L929) cytotoxicity assay in the presence of actinomycin D [21]. 
Resu l ts  and  d iscuss ion  
Epitope mapping on the S-antigen 
Monoclonal antibodies $2D2 and $6H8 to S-antigen can inhibit the EAU induced 
by S-antigen immunization [16, 17]. We identified the epitope recognized by these 
inhibitory mAbs using the PEPSCAN method [29]. The epitope $2 was localized to 
residues 40 to 50 of S-antigen, corresponding to the sequence PVDGVVLVDPE 
(Figure la). This sequence is conserved in retina and pineal gland S-antigens from 
various mammals and in bovine [3-arrestin, and is immunochemically detectable in
other vertebrates, invertebrates [25] and even in plants [14]. The epitope $2 is 
situated far from the presently known disease-inducing [2, 32-38] and T-cell stimu- 
lating [34--36] sites. The possible action ofepitope $2 in immunoregulation s further 
implied by the finding that the humoral immune response against his epitope is 
related to disease inducibility in genetically distinct rat strains: indeed, the antibody 
response to $2 is low in susceptible Lewis rats, high in refractory Brown Norway 
(BN) and Long Evans strains, and intermediate in susceptible Lewis x BN F1 
hybrids [39]. 
Biological function of epitope $2 
These observations prompted us to test a possible direct effect of epitope $2 on 
the production of inflammatory c tokines uch as TNFa [18]. For this approach, 
adherent human PMNL were employed to study the conditions that regulate TNFa 
synthesis in vitro. S-antigen and peptide $2 (EPVDGVVLVDPE) were found to 
induce hTNFa mRNA (Figure 3a) and IL-113 mRNA expression (data not shown). 
In addition, detectable amounts of released hTNFa protein were measured in a 
hTNFa specific ELISA (Table 1) and in the TNFa bioassay (data not shown). These 
results suggest that the EAU suppressive mAbs inhibit TNFa induction and/or 
influence one of the TNFa mediated pleiotropic effects. However, under in vitro 
conditions, we could not demonstrate any effect of the mAbs $2D2 and $6H8 either 
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Figure 1. Immunoreactivity profile of(a) 68 heptapeptides, overlapping by six amino acids, from bovine 
retinal S-antigen (N-terminal residue 1-74) and (b) of 75 heptapeptides, overlapping by five amino acids, 
from the complete mature hTNFa molecule. The S-antigen/hTNF~ common epitopes were revealed 
with mAb $6H8 (I ~ag/ml). 
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Tab le  1. h TNFa release, stimulated by protein or peptides 
TNFa (ng/ml) 
Not stimulated 
S-antigen 
Peptide $2 
hTNFa peptides 
Residues 31-42 
Residues 37-48 
Residues 43-54 
Residues 49-60 
Residues 79-90 
Residues 25-36 
Residues 31-53 
EPVDGVVLVDPE 
RRANALLANGVE 
LANGVELRDNQL 
LRDNQLVVPSEG 
VVPSEGLYLIYS 
TISRIAVSYQTK 
QLQWLNRRANAL 
RRANALLANGVELRDNQLVVPSE 
< 1.0 
5.4 
3.6 
2.5 
1.9 
1.7 
< 1.0 
<1.0 
< 1.0 
20.4 
TNFa release was determined in the supematant of human PMNL cultures after 20h incubation with 
10 lag/ml of the indicated preparations. TNFct concentrations were determined in the hTNFa specific 
ELISA. 
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Figure 2. Western blot analysis of recombinant hTNFa using mAbs 7D I against hTNFa (lane 1), $2D2 
(lane 2) and $6H8 (lane 3) against S-antigen and control mAbs ALB9 (lane 4), PM1 (lane 5) and ALB2 
(lane 6) with unrelated specificities. Numbers on the left indicate molecular weight markers. 
on the induction ofmonocyte activation by TNFa  itself for TNFa  biosynthesis or on 
the cytotoxic effects of TNFa  in the bioassay (data not shown). 
Epitope mapping on TNFa 
By Western blot analysis, we found that mAbs $2D2 and $6H8 specifically recognize 
hTNFa  in both its monomeric and dimeric forms (Figure 2). A PEPSCAN analysis 
of hTNFct was therefore performed using mAbs that recognize epitope $2 of S- 
antigen. The analysis revealed a cross-reactive epitope in the hTNFa  molecule at 
residues 39 to 45, i.e., peptide NGVELRD (Figure lb). The common motif  in the 
sequences 40-50 of S-antigen (PVDGVVLVDPE)  and 39-45 of hTNFa  
(NGVELRD)  is GVxLxD.  Examination of the protein sequence data bank 
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Table 2. Vertebrate proteins containing the G VxLxD motif (from protein sequence data 
banks SwissProt and NBRF) 
Retinal S-antigen (bovine, human, mouse and rat) 
Pineal gland S-antigen (rat) 
[3-arrestin (bovine) 
Tumor necrosis factor a (human and bovine) 
Coagulation factor VIII precursor (human) 
Complement components C4 and C9 (human and mouse) 
Integrin beta-4 subunit precursor (human) 
Interferon-induced 17 kDa protein, interferon-induced 15 kDa protein (human) 
Cholesteryl ester transfer protein precursor (human) 
Acetyl-CoA acetyltransferase (EC.2.3.1.9.) 
Liver glucose transporter protein (human and mouse) 
Lysozyme C (rat and mouse) 
Lysozyme M (mouse) 
cAMP-dependent 3',5'-cyclic phosphodiesterase 1-4 (rat) 
Complement component C4-related sex-limited protein (mouse) 
Prolactin precursor 
Hemoglobin I and III (chicken) 
Band 3 anion transport protein (chicken) 
Cytochrome P450 IVB1 (rabbit) 
(SwissProt and NBRF) identified the GVxLxD motif in other vertebrate proteins as 
well as in S-antigen and TNF~ (Table 2). 
Biological function of TNF~ peptides 
The finding of an hTNFa region that cross-reacts with the S-antigen mAbs 
suggested that this antigenic determinant might be associated with the autocrine 
stimulatory potential of hTNFa [21]. Indeed, the hTNFa-dodecapeptides, 
RRANALLANGVE (residues 31 to 42), LANGVELRDNQL (37 to 48) and 
LRDNQLVVPSEG (43 to 54), covering the area of the epitope common with 
S-antigen were able to activate human PMNLs, whereas a series of other hTNFa-  
derived dodecapeptides, including peptides positioned irectly adjacent o the 
region of homology, did not induce TNFa mRNA (Figure 3b and c) and IL-I~ 
mRNA expression (data not shown). In addition to hTNFa mRNA expression, we 
studied (as for S-antigen and peptide $2) the influence of these three dodecapeptides 
on the induction of biologically active hTNFa protein. Small but measurable 
amounts of hTNFa protein were released after stimulation of PMNL with the 
hTNFa peptides (Table 1). Essentially identical results were obtained in the TNFct 
bioassay (data not shown). A synthetic peptide covering the hTNFa sequence from 
residue 31 to 53, (RRANALLANGVELRDNQLVVPSE) (peptide RRAN), and 
including the complete region of homology, showed an efficiency on hTNFa mRNA 
expression comparable with that of rhTNFa itself (Figure 3d). The failure of the 
other hTNFa dodecapeptides to induce TNFa expression i dicated that contami- 
nating endotoxin levels in the protein and synthetic peptide preparations were not 
responsible for the observed human PMNL activation. S-antigen-, peptide $2- or 
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Figure 3. Induction of TNFa mRNA expression i cultures of the adherent fraction of human per- 
ipheral mononuclear cells. Monocytes were either not stimulated, orstimulated with one of the following 
preparations: (a)Staphylococcus aureus (10 I~g/ml), S-antigen (2 I.tg/ml), peptide $2 (EPVDGVVLVDPE) 
(2 I~g/ml), hTNFa (1 Ilg/ml); (b) 1 lag/ml of hTNFa, peptide $2, hTNFa specific peptides aa 1 to 12 
(VRSSSRTPSDKP), 37 to 48 (LANGVELRDNQL), 43 to 54 (LRDNQLVVPSEG), 73 to 84 
(HVLLTHTISRIA), 31 to 42 (RRANALLANGVE), 67 to 78 (QGCPSTHVLLTH); (c) 1 Ng/ml 
hTNFct or hTNFtz specific peptides aa 25 to 36 (QLQWLNRRANAL), 27 to 38 (QWLNRRANALLA), 
31 to 42 (RRANALLANGVE), 37 to 48 (LANGVELRDNQL), 43 to 54 (LRDNQLVVPSEG), 49 to 60 
(WPSEGLYLIYS),  79 to 90 (TI SRIAVSYQTK); (d) 1 lag/ml ofhTNFa, or hTNFa peptide RRAN, aa 
31 to 53 (RRANALLANGVELRDNQLVVPSE). 
hTNFct-derived peptides did not interfere in the hTNFa specific EL ISA  and were 
not directly cytotoxic to the target cells used in the TNFa  bioassay. Even when cross~ 
linking ofpeptide RRAN was achieved with the mAbs $2D2 and $6H8, no cytotoxic 
effect was detectable on TNFa  sensitive murine or human tumor cells [40]. In 
addition, S-antigen, peptide $2 and peptide RRAN were not able to stimulate PGE 2 
production in a mouse fibroblast line (L929) as did hTNF~ (data not shown). 
These data provide new insight into the mechanism of autocrine-stimulated 
hTNFa gene expression, defining a functional structure in the hTNFu molecule for 
PMNL activation. This is also supported by recent data demonstrating fibroblast 
chemotaxis induced by a hTNFa peptide aa (31-68) [41]. The  identified region is 
highly conserved among TNFa  sequences derived from several species [42, 43] and 
has been predicted to be a potential receptor binding site [44-46]. However, on two 
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different cell lines we were not able to demonstrate competition of peptide RRAN 
with radiolabelled rhTNFa for receptor binding. 
TNFa  production stimulated by S-antigen, peptide, $2, hTNFa itself and the 
peptide RRAN could play a direct role in local inflammatory processes, for example 
in ocular autoimmune disease. Modifications of peptide RRAN to produce peptide 
variants with agonistic or antagonistic a tivity or the production of chemical inhibi- 
tors for this region in the TNFa  molecule are future experimental or treatment 
perspectives. The inhibitory effect of mAbs $2D2 and $6H8 on EAU induction 
could be explained by their binding to the TNFa-inducing site(s) of the S-antigen 
and a blockade of the TNFa inducing function. However, adirect neutralizing effect 
of these mAbs on the monocyte activating capacity of S-antigen, peptide $2 or 
peptide RRAN in the described TNFt~ production i vitro system was not observed 
(data not shown). Therefore, in the EAU model, active immunization programmes 
are underway using peptide $2, peptide RRAN and/or human S-antigen peptides 
covering peptide $2 region (peptide 4: aa 31-50 and peptide 5: aa 41-60) in order to 
protect against S-antigen induced EAU and EAP. Preliminary results uggest that 
suppression of EAU is related to the immune response against he homologous 
sequence of S-antigen and TNFa (Y. De Kozak, personal communication). EAU 
and EAP induced by the retinal autoantigens rhodopsin and interstitial retinoid 
binding protein (IRBP) [1] and experimental autoimmune ncephalomyelitis 
induced by myelin basic protein, could serve as model systems for the putative 
contribution of TNFa to several human neurological diseases [47-49]. The possi- 
bility of direct cytokine induction by autoantigens, bypassing the necessity for 
specific antigen recognition, by T/B cells deserves investigation i such models of 
autoimmune diseases. 
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